The Claim
Long-term suppressive levothyroxine therapy (150–184 mcg/day for 3–5 years) in premenopausal women with multinodular goiter or postsurgical thyroid carcinoma is associated with significantly elevated serum osteocalcin levels compared to matched controls without thyroid hormone suppression.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Premenopausal women taking high-dose levothyroxine for 3 to 5 years for thyroid conditions have higher levels of osteocalcin in their blood than similar women not on this therapy, indicating increased bone turnover.
See the scientific wording
Long-term suppressive levothyroxine therapy (150–184 mcg/day for 3–5 years) in premenopausal women with multinodular goiter or postsurgical thyroid carcinoma is associated with significantly elevated bone turnover, as indicated by higher serum osteocalcin (BGP) levels (9.6 ± 2.2 ng/mL vs. 6.7 ± 2.3 ng/mL; p < 0.0006), compared to matched controls without thyroid hormone suppression, suggesting a potential impact on skeletal metabolism in this subgroup.
Too much thyroid hormone makes bone-building and bone-breaking cells work faster, causing more bone material to be released into the blood.
What the research says
1 studyThis study found that women taking high doses of thyroid hormone for several years had higher levels of a blood protein that signals bones are breaking down faster, compared to women not taking the medicine. This suggests the medicine might affect bone health in this group.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.